UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): April 4, 2005



                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)


              Florida                       0-27937               65-0142474
              -------                       -------               ----------
(State or Other Jurisdiction of     (Commission File Number)    (IRS Employer
         Incorporation)                                      Identification No.)


            1055 Hastings Street, Suite 1900
              Vancouver, British Columbia                     V6E 2E9
              ----------------------------                    -------
        (Address of Principal Executive Offices)            (Zip Code)


                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Section 7 - Regulation FD
-------------------------

Item 7.01  Regulation FD Disclosure

     Dragon   Pharmaceutical  Inc.  announced  its  business  update  after  the
completion of acquisition of Oriental Wave and selected unaudited 2004 pro-forma
combined financial data on the attached press release.


Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01  Financial Statements and Exhibits

     Exhibit No.    Exhibit Description
     ----------     -------------------

         99         Press   release   announcing   business   update  after  the
                    completion  of  acquisition  of Oriental  Wave and  selected
                    unaudited 2004 pro-forma combined financial data



<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                       DRAGON PHARMACEUTICAL INC.,
                                       a Florida Corporation


Dated:  April 5, 2005                  /s/ Maggie Deng
                                       ----------------------------------------
                                       Maggie Deng
                                       Chief Operating Officer



<PAGE>


                                  EXHIBIT INDEX


     Exhibit No.    Description

          99        Press   release   dated   April  4,  2005   titled   "Dragon
                    Pharmaceutical   Announces   Business   Update   after   the
                    Completion  of  Acquisition  of Oriental  Wave and  Selected
                    Unaudited 2004 Pro-forma Combined Financial Data "
[{"type": "8-K", "sequence": "1", "filename": "for040405.txt", "description": "FORM 8-K FOR EVENT APRIL 4, 2005", "secsgml_size_bytes": 3717}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "05740803"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): April 4, 2005

                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)

              Florida                       0-27937               65-0142474
              -------                       -------               ----------
(State or Other Jurisdiction of     (Commission File Number)    (IRS Employer
         Incorporation)                                      Identification No.)

            1055 Hastings Street, Suite 1900
              Vancouver, British Columbia                     V6E 2E9
              ----------------------------                    -------
        (Address of Principal Executive Offices)            (Zip Code)

                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 7 - Regulation FD
-------------------------

Item 7.01  Regulation FD Disclosure

     Dragon   Pharmaceutical  Inc.  announced  its  business  update  after  the
completion of acquisition of Oriental Wave and selected unaudited 2004 pro-forma
combined financial data on the attached press release.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01  Financial Statements and Exhibits

     Exhibit No.    Exhibit Description
     ----------     -------------------

         99         Press   release   announcing   business   update  after  the
                    completion  of  acquisition  of Oriental  Wave and  selected
                    unaudited 2004 pro-forma combined financial data
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       DRAGON PHARMACEUTICAL INC.,
                                       a Florida Corporation

Dated:  April 5, 2005                  /s/ Maggie Deng
                                       ----------------------------------------
                                       Maggie Deng
                                       Chief Operating Officer
EXHIBIT INDEX

     Exhibit No.    Description

          99        Press   release   dated   April  4,  2005   titled   "Dragon
                    Pharmaceutical   Announces   Business   Update   after   the
                    Completion  of  Acquisition  of Oriental  Wave and  Selected
                    Unaudited 2004 Pro-forma Combined Financial Data "